#diversity

A University of Toronto’s graduate program aims to improve the quality of care for Black patients, who have long experienced health inequity

A new study is investigating the genetic differences that leave Black men more susceptible to prostate cancer.

Yet 83% of Black people with metastatic breast cancer expressed interest in participating in trials.

A study found that only 43% of clinical trials reported race and ethnicity. The FDA issued guidance to address these inequalities.

In clinical trials for personalized cancer treatments, Black and Latino people are routinely understudied compared with whites.

Count Me In (CMI) is launching its first patient-partnered research project translated entirely to Spanish.

The genetic variant frequently causes low white blood cell counts in African Americans who are otherwise healthy.

The fund will help to develop initiatives to support researchers of color and increase diversity in cancer research and patient care.

The Senate-passed bill memorializing Henrietta Lacks aims to address underrepresentation in cancer clinical trials.

The new collaboration will dig into tumor genome, microbiome to address colon cancer inequities among people of color.

With Stand Up To Cancer, he hopes to increase diversity in this field so all patients can benefit equally from potential cancer treatments.

The group of 15 medical students promotes medicine as a career choice for Black people.

The program’s home will be Callen-Lorde’s in-the-works site in downtown Brooklyn.

Medical students graded their institutions. Despite improvements, no school earned an A.

The study raises concerns about the effectiveness of cancer drugs, as genetic differences may affect how someone responds to a drug.

Can data from more than 1 million Americans accelerate research and medical breakthroughs that benefit everyone?